A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain

References

• Guez M, Hildingsson C, Nasic S, Toolanen G. Chronic low back pain in individuals with chronic neck pain of traumatic and non-traumatic origin: a population-based study. Acta Orthop 2006;77:132–7
   PubMed Web of Science ®Google Scholar
• Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine 1995;20:11–9
   Google Scholar
• Ekman M, Johnell O, Lidgren L. The economic cost of low back pain in Sweden in 2001. Acta Orthop 2005;76: 275–84
   Google Scholar
• Kent PM, Keating JL. The epidemiology of low back pain in primary care. Chiropr Osteopat 2005;13:13
   PubMedGoogle Scholar
• Kalso E, Allan L, Dobrogowski J, et al. Do strong opioids have a role in the early management of back pain? Recommendations from a European expert panel. Curr Med Res Opin 2005;21:1819–28
   PubMed Web of Science ®Google Scholar
• Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005;65:S32–S49
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21–8
   Google Scholar
• Ruoff GE, Rosenthal N, Jordan D, et al. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther 2003;25:1123–41
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772–8
   PubMed Web of Science ®Google Scholar
• Lemmens HJ, Wada DR, Munera C, et al. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials 2006;27:165–73
   PubMed Web of Science ®Google Scholar
• Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the ‘address’ recognition locus. J Med Chem 2001;44:857–62
   PubMed Web of Science ®Google Scholar
• Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911–8
   Google Scholar
• Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;6:357–66
   Google Scholar
• Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 2005;13:57–65
   Google Scholar
• Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004;24:468–76
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988;43:72–8
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988;247:47–53
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine– naloxone tablet. Drug Alcohol Depend 2000;58:143–52
   Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253–9
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–58
   PubMed Web of Science ®Google Scholar
• Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage 2006;31:369–77
   Google Scholar
• Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. J Am Med Assoc 2005;293:3043–52
   Google Scholar
• Ahdieh H, Ma T, Babul N, Lee D. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 2004;44:767–76
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372–80
   PubMed Web of Science ®Google Scholar
• Rives PA, Douglass AB. Evaluation and treatment of low back pain in family practice. J Am Board Fam Pract 2004;17(Suppl): S23–S31
   Google Scholar
• American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. Chicago (IL): American Pain Society; 2002
   Google Scholar
• Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998;23:2591–600
   Google Scholar
• Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30:2484–90
   PubMed Web of Science ®Google Scholar
• Simpson Jr RK, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage 1997;14:218–24
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Galer BS, Lacouture P, et al. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 2003;4:21–30
   PubMed Web of Science ®Google Scholar
• Malonne H, Coffiner M, Fontaine D, et al. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005;30: 113–20
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533–8
   PubMed Web of Science ®Google Scholar
• Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain 1995;60:267–74
   Google Scholar
• Kamijima K, Kuboki T, Kumano H, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 2005;20:265–73
   PubMed Web of Science ®Google Scholar
• Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214–9
   PubMed Web of Science ®Google Scholar
• Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998;19:178–87
   PubMedGoogle Scholar
• Deuschle M, Krumm B, Bindeballe N, et al. Open-label non-randomized versus double-blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization? Pharmacopsychiatry 2004;37:299–302
   PubMed Web of Science ®Google Scholar